Comparison of the Therapeutic Effects of VR and VR + GnRHa in the Treatment of Cesarean Scar Diverticula
Cesarean Scar Diverticula
About this trial
This is an interventional treatment trial for Cesarean Scar Diverticula focused on measuring cesarean scar diverticula, vaginal repair, GnRHa
Eligibility Criteria
Inclusion Criteria:
- Patients are younger than 40.
- Clearly diagnosed with CSD.
- Experiencing clinical features of abnormal uterine bleeding, prolonged menstrual flow (the duration of menstruation is more than 7 days).
- The thickness of the remaining muscular layer of CSD was less than 3 mm.
- The women are at least 20 years old with singleton pregnancies and had undergone a cesarean delivery after at least 37 weeks of gestation.
- The medicine conservative treatment is invalid.
- Refusing or use birth control pills contraindications.
- No serious medical problems (important viscera function in the normal range).
- No uterine fibroids, endometriosis, adenomyosis, and patients with ovarian cysts.
- No gynaecology or other malignant tumors.
- Sign the informed consent.
Exclusion Criteria:
- Over the age of 40;
- Indefinite diagnosis.
- The absence of clinical manifestations of CSD.
- The presence of menstrual irregularities before cesarean delivery.
- Coagulation disorders.
- Malignant tumors.
- With severe medical problems (severe liver disease, kidney disease, respiratory diseases, heart disease or uncontrolled diabetes, epilepsy, etc., dysfunction of important organs).
- Known chronic inflammatory diseases, any other uterine diseases (such as uterine fibroids, endometriosis and adenomyosis), uterine surgery except cesarean section.
- Use of intrauterine devices.
- Unwilling to comply with the research plan.
Sites / Locations
- Department of Gynecology, Shanghai First Maternity and Infant Hospital, affiliated to Tongji University
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
VR + GnRHa
VR
CSD patients were treated with vaginal repair of CSD in combination with GnRHa (Zoladex, 3.6 mg, AstraZeneca, Macclesfield, United Kingdom) as a subcutaneous injection (abbreviated as VR + GnRHa). In the group of VR + GnRHa, 2 doses of GnRHa were administered. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure. The detailed procedure of VR has been described in our previous study (Zhou et al., 2016).
CSD patients were treated with vaginal repair of CSD in combination with 0.01 ml saline as a subcutaneous injection (abbreviated as VR). In the group of VR, 2 doses of saline were administered. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure. The detailed procedure of VR has been described in our previous study (Zhou et al., 2016).